two
major
ebola
viru
outbreak
africa
zika
viru
brazil
current
sever
acut
respiratori
syndrom
coronaviru
declar
world
health
organ
pandem
occur
past
decad
case
strong
sens
vu
scientist
involv
drug
discoveri
lack
avail
antivir
treat
infect
patient
lead
clamor
test
anyth
avail
pharmaceut
compani
charg
offer
drug
also
seem
see
similar
pattern
respons
across
outbreak
rush
first
sens
prioriti
might
lead
best
even
outcom
patient
alway
immedi
propos
creat
vaccin
pronounc
avail
short
time
end
year
actual
outbreak
question
never
happen
within
optimist
artifici
deadlin
experienc
current
outbreak
ebola
vaccin
readi
second
outbreak
approv
govern
calm
popul
time
need
seen
someth
vanquish
viru
case
result
pneumonia
share
aspect
patholog
pathogenesi
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
sarscov
merscov
belong
famili
coronavirida
genu
betacoronaviru
sever
drug
compani
immedi
made
antivir
avail
exampl
abbvi
made
hiv
approv
drug
lopinavirritonavir
combin
avail
chines
govern
drug
previous
suggest
promis
base
combin
studi
result
marmoset
studi
public
alreadi
appear
describ
use
drug
patient
korea
significantli
decreas
viral
load
simultan
gilead
made
avail
remdesivir
previous
fail
clinic
trial
ebola
recent
shown
activ
mer
rhesu
macaqu
remdesivir
chloroquin
sever
drug
test
vitro
tabl
shown
activ
research
also
suggest
earli
januari
treatment
option
might
like
includ
lopinavirritonavir
remdesivir
favilavir
arbidol
well
broad
array
nucleosid
analog
neuraminidas
inhibitor
peptid
rna
synthesi
inhibitor
antiinflammatori
drug
tradit
chines
medicin
need
treatment
option
import
learn
transmiss
see
increas
number
travelrel
infect
alreadi
past
week
seen
rapid
spread
itali
mani
countri
includ
brazil
beyond
viru
outbreak
greatli
strain
healthcar
system
affect
countri
test
everi
aspect
infrastructur
suppli
chain
prepared
rais
question
learn
past
drug
discoveri
effort
attempt
develop
addit
drug
effici
acceler
global
data
gener
effect
coupl
month
remark
howev
scientif
inform
gap
imped
progress
toward
smallmolecul
treatment
still
perceiv
mani
persist
first
outlin
ebola
back
thu
make
thenandnow
comparison
see
supplementari
materi
fig
tabl
onlin
well
share
experi
research
viru
outbreak
effort
ebola
drug
discoveri
initi
start
comput
pharmacophor
analysi
small
number
vitro
ebola
activ
compound
follow
identifi
summar
fdaapprov
drug
could
use
viru
highlight
variou
strategi
next
viru
outbreak
step
preced
pivot
point
us
develop
machin
learn
model
ebola
viru
deriv
vitro
data
earli
drug
identifi
screen
antimalari
amodiaquin
subsequ
shown
associ
decreas
mortal
drug
artesun
amodiaquin
use
malaria
treatment
ebola
patient
wherea
other
took
differ
malaria
medicin
artemetherlumefantrin
ebola
machin
learn
model
use
select
three
molecul
vitro
test
identifi
pyronaridin
tiloron
quinacrin
good
vitro
activ
nm
ebola
viru
preliminari
data
enabl
us
obtain
fund
nih
take
one
compound
vivo
test
also
leverag
nih
support
collabor
test
two
compound
well
molecul
test
mous
model
ebola
infect
demonstr
signific
efficaci
pyronaridin
current
pursu
larger
anim
model
ebola
viru
infect
work
comput
model
vitro
test
happen
space
month
wherea
took
sever
year
obtain
fund
first
mous
studi
mean
streamlin
approach
drug
discoveri
cost
effect
amount
data
ultim
gener
led
revit
interest
molecul
pull
togeth
team
research
brazil
usa
provid
suggest
open
drug
discoveri
effort
zika
viru
includ
variou
comput
strategi
repurpos
molecul
dock
zika
protein
also
describ
resourc
molecul
could
priorit
test
follow
homolog
model
everi
zika
viru
protein
week
first
crystal
structur
zika
protein
releas
work
perform
open
attract
attent
ibm
world
commun
grid
team
request
submit
propos
zika
project
use
distribut
comput
facil
becam
openzika
project
led
team
brazil
usa
involv
dock
million
molecul
zinc
databas
zika
viru
relat
flaviviru
protein
crystal
structur
sinc
also
perform
model
zika
protein
analysi
first
year
follow
outbreak
recent
effort
led
discoveri
inhibitor
helicas
learn
openzika
project
streamlin
futur
open
scienc
project
would
follow
would
pick
fewer
target
dock
molecul
openzika
project
creat
billion
dock
result
ten
target
take
mani
year
process
would
also
suggest
best
work
highresolut
crystal
structur
versu
homolog
model
soon
possibl
would
also
start
librari
commerci
avail
drug
antivir
would
massiv
limit
number
molecul
dock
thousand
found
dock
zinc
librari
avail
time
led
compound
readili
avail
focus
librari
interest
option
perform
targetdirect
virtual
screen
exampl
chemdiv
asinex
databas
specif
subset
proteas
inhibitor
exampl
facilit
acceler
experiment
screen
openzika
learnt
multipl
biolog
lab
commit
test
vitro
also
import
access
experiment
result
quickli
valid
comput
approach
work
ibm
world
commun
grid
includ
fund
found
difficult
obtain
nih
fund
support
project
begin
comput
also
attempt
small
busi
grant
academ
collabor
without
success
even
though
leverag
massiv
comput
resourc
world
commun
grid
would
recommend
open
effort
like
need
fund
vitro
valid
million
dollar
invest
nih
fund
zika
research
project
sinc
outbreak
yet
small
molecul
note
drug
discoveri
pipelin
still
therefor
unmet
medic
need
treatment
zika
viru
comput
effort
could
aid
costeffect
whole
genom
sequenc
isol
patient
sever
countri
brazil
canada
china
germani
korea
usa
made
rapidli
avail
global
initi
share
influenza
data
gsaid
platform
genom
sampl
decemb
februari
sampl
found
close
relat
mutat
rel
common
ancestor
preliminari
genet
analysi
indic
brazilian
genom
differ
three
mutat
wuhan
refer
strain
two
mutat
share
closest
sequenceth
germani
strain
space
week
acknowledg
latest
coronaviru
outbreak
sever
laboratori
start
deposit
homolog
model
main
viral
proteas
protein
use
server
itass
other
perform
dock
model
develop
model
understand
viru
enter
cell
model
spike
protein
human
angiotensinconvert
enzym
protein
interact
time
write
structur
avail
main
proteas
complex
inhibitor
pdb
id
subunit
spike
glycoprotein
receptorbind
domain
post
fusion
core
subunit
domain
use
overview
provid
search
entir
viru
sequenc
protein
data
bank
pdb
see
supplementari
materi
fig
onlin
comparison
zika
took
sever
month
begin
outbreak
singl
protein
avail
pdb
spike
glycoprotein
respons
fusion
viral
membran
hostcel
membran
viru
matur
cleav
subunit
attach
virion
cell
membran
interact
host
receptor
mediat
fusion
virion
cellular
membran
recent
studi
report
spike
protein
bind
higher
affin
sarscov
one
cryoem
structur
spike
protein
low
resolut
without
human
protein
time
write
paper
prefer
build
model
homolog
model
see
supplementari
materi
method
onlin
use
spike
protein
model
avail
sarscov
spike
protein
crystal
structur
pdb
align
structur
compar
residu
interfac
residu
virus
seen
fig
residu
sarscov
moreov
residu
conserv
physicalchem
featur
except
residu
polar
sar
hydrophob
fig
main
proteas
pro
coronavirus
cystein
proteas
particip
viral
replic
cleav
polyprotein
pro
organ
three
domain
activ
homodim
form
align
crystal
structur
pro
sarscov
merscov
compar
structur
residu
catalyt
site
catalyt
site
sarscov
wherea
merscov
fig
catalyt
site
local
interfac
domain
residu
ii
third
domain
residu
ctermin
consist
loop
region
requir
dimer
recent
report
structur
pro
sarscov
high
ident
function
structur
equival
pro
sarscov
merscov
demonstr
coronaviru
proteas
promis
target
develop
broadspectrum
antivir
virus
drug
repurpos
offer
potenti
faster
approach
identifi
drug
alreadi
approv
use
might
work
diseas
interest
type
strategi
attempt
merscov
sarscov
repurpos
hostbas
therapi
also
propos
coronavirus
sever
studi
screen
hundr
molecul
test
activ
merscov
sarscov
tabl
first
screen
fdaapprov
drug
identifi
four
fdaapprov
drug
includ
chloroquin
chlorpromazin
loperamid
lopinavir
time
second
studi
screen
compound
identifi
fdaand
nonfdaapprov
drug
includ
chloroquin
among
mani
hit
kinas
inhibitor
imatinib
impact
earli
stage
infect
intern
endosom
traffick
latter
molecul
appear
work
inhibit
fusion
viral
membran
chloroquin
wide
use
malaria
loperamid
use
diarrhea
repres
drug
readili
avail
mani
locat
around
world
physician
also
familiar
sideeffect
profil
ligand
dataset
screen
use
appli
machin
learn
method
produc
predict
model
use
screen
compound
librari
suggest
superposit
sarscov
spike
protein
highlight
interfac
bind
pocket
zoom
residu
spike
correspond
sarscov
spike
fig
experiment
detail
describ
supplementari
materi
onlin
bayesian
model
also
avail
http
advantag
approach
method
fast
requir
crystal
structur
enabl
smallmolecul
structur
score
mani
model
simultan
wellestablish
principl
relev
enzym
assay
proteinprotein
interact
antagon
viral
infect
determin
run
collect
approv
drug
howev
neither
trivial
get
definit
list
structur
silico
prepar
dock
acquir
physic
collect
readi
screen
even
though
variou
repurpos
subset
avail
vendor
notwithstand
approxim
definit
approv
set
select
pubchem
intersect
curat
drug
resourc
drugbank
drugcentr
iupharbp
guid
pharmacolog
total
molecul
respect
threeway
compoundsincommon
total
chemic
identifi
cid
pubchem
indic
molecul
avail
chemic
vendor
relax
stringenc
repurpos
provid
triag
step
altern
screen
everi
approv
drug
take
one
class
compound
exampl
taken
opportun
dock
fdaapprov
proteas
inhibitor
amprenavir
atazanavir
darunavir
fosamprenavir
indinavir
lopinavir
nelfinavir
ritonavir
saquinavir
tipranavir
hepat
c
proteas
inhibitor
asunaprevir
boceprevir
grazoprevir
paritaprevir
simeprevir
telaprevir
pro
structur
dock
perform
two
differ
commerci
dock
softwar
product
biovia
discoveri
studio
glide
best
dock
result
compar
see
supplementari
materi
tabl
onlin
result
dock
approach
indic
azatanavir
lopinavir
could
interest
vitro
vivo
test
fig
atazanavir
interact
pro
hbond
amid
group
aromat
ring
atazanavir
ligandfit
score
also
form
hydrophob
interact
residu
relat
lopinavir
ligandfit
score
hbond
establish
residu
nitrogen
atom
carbam
group
similar
hydrophob
interact
observ
lopinavir
fig
china
south
korea
lopinavir
mgritonavir
mg
alreadi
use
treatment
day
lopinavirritonavir
administr
viral
load
start
decreas
detect
littl
coronaviru
titer
observ
sinc
lopinavir
coformul
ritonavir
commerci
avail
known
around
worldit
formulari
hiv
contrast
atazanavir
less
commonli
use
wide
produc
distribut
quickli
exist
channel
import
ensur
hiv
patient
lose
access
medic
need
also
medic
clinician
familiar
term
side
effect
unlik
less
commonli
use
medic
broader
analysi
fdaapprov
drug
dock
proteas
structur
could
point
drug
worth
test
also
perform
dock
calcul
spike
glycoprotein
complex
host
protein
fdaapprov
drug
molecul
use
glide
softwar
one
cryoem
structur
spike
protein
low
resolut
without
human
protein
time
analysi
prefer
build
model
homolog
model
lowerresolut
structur
higher
show
basic
contour
protein
chain
atom
structur
must
infer
built
spike
subunit
model
use
swissmodel
server
templat
use
sarscov
spike
protein
pdb
id
resolut
sequenc
ident
spike
protein
protein
refin
ad
human
protein
model
base
sarscov
structur
pdb
id
built
full
spike
model
see
fig
supplementari
materi
onlin
qualiti
statist
model
spike
good
residu
lie
favor
region
ramachandran
plot
molprob
score
intermolecular
interact
atazanavir
lopinavir
b
main
proteas
structur
pdb
id
obtain
dock
represent
left
hbond
present
magenta
dash
line
color
code
carbon
oxygen
nitrogen
hydrogen
atom
grey
red
blue
white
respect
interact
diagram
right
hbond
present
magenta
arrow
pymol
softwar
use
visual
inspect
dock
pose
render
molecular
imag
model
avail
see
supplement
materi
pdb
file
onlin
subsequ
perform
dockingbas
virtual
screen
grid
center
spike
interfac
seen
tabl
dock
score
indic
rizatriptan
antimigrain
agent
glide
score
kcal
mol
dasabuvir
antivir
hepat
c
glide
score
kcal
mol
pravastatin
lipidlow
agent
glide
score
kcal
mol
empagliflozin
hypoglycem
agent
glide
score
kcal
mol
could
interest
vitro
test
detail
intermolecular
interact
intermolecular
interact
rizatriptan
dasabuvir
b
pravastatin
c
empagliflozin
interfac
light
blue
green
respect
represent
left
hbond
present
magenta
dash
line
color
code
carbon
oxygen
nitrogen
hydrogen
atom
grey
red
blue
white
respect
spike
subunit
color
blue
human
light
blue
ligandinteract
diagram
right
hbond
pp
stack
pcation
interact
present
magenta
green
red
line
respect
glide
softwar
use
dock
ligand
grid
center
residu
wwwdrugdiscoverytodaycom
drug
interfac
shown
fig
summari
drug
form
pcation
interact
pp
interact
hbond
good
agreement
result
previou
studi
suggest
earli
high
dose
statin
pravastatin
could
crucial
surviv
merscov
infect
suggest
molecul
could
valid
futur
vitro
experi
modern
drug
discoveri
effort
tri
elimin
ineffici
increas
knowledg
extens
util
gener
data
guid
new
experi
therefor
also
taken
drug
repurpos
approach
base
polypharmacolog
use
method
call
molecular
biolog
signatur
profil
approach
guid
artifici
intellig
capabl
present
complex
relationship
chemic
substanc
molecular
target
cell
andor
organ
could
creat
complet
understand
multibiolog
profil
caus
drug
analyz
respons
diseas
exampl
appli
drug
ritonavir
favipiravir
ribavirin
chloroquin
scaffold
find
new
potenti
molecular
biolog
signatur
profil
search
nonobvi
mechanismofactionbas
associ
drug
molecular
target
diseas
fig
supplementari
materi
fig
tabl
onlin
compar
molecular
biolog
signatur
ritonavir
drug
found
drug
cobicistat
carfilzomib
ombitasvir
present
highest
match
score
suggest
drug
could
interest
although
alreadi
sever
drug
assess
clinic
still
need
identifi
addit
treatment
altern
offset
drug
shortag
possibl
discov
molecul
increas
efficaci
safeti
costeffect
previous
propos
appli
comput
drug
discoveri
approach
machin
learn
dock
molecular
biolog
signatur
profil
gener
ritonavir
compar
drug
use
artifici
intellig
creat
thousand
decisionmak
mimic
biolog
respons
interact
small
molecul
multipl
enzym
target
offtarget
vitro
vivo
endpoint
drug
cobicistat
carfilzomib
ombitasvir
present
higher
match
score
ritonavir
aid
discoveri
new
candid
molecul
ebola
zika
respect
learnt
effort
appli
demonstr
howev
research
case
move
much
faster
pace
initi
deliv
first
crystal
structur
week
first
public
notif
viru
compani
mobil
bring
drug
patient
clinician
use
prior
vitro
research
propos
compound
activ
merscov
sarscov
suggest
treatment
current
clinic
use
broadspectrum
antivir
usa
would
invalu
situat
like
virus
identifi
medic
sideeffect
profil
known
clinician
alreadi
produc
scale
avail
local
pharmaci
around
world
allow
patient
treat
especi
travel
restrict
quarantin
could
reduc
product
distribut
certain
drug
remain
import
need
medic
baselin
hiv
patient
take
ritonavirlopinavir
abl
continu
access
medic
need
els
risk
poor
clinic
outcom
antivir
resist
patient
although
virus
flu
might
kill
patient
usa
season
far
crippl
financi
impact
remain
seen
global
past
ebola
zikv
merscov
sarscov
outbreak
anyth
go
pandem
far
signific
multipl
effect
treatment
avail
rapidli
deliv
patient
could
save
live
also
supplement
treatment
combin
comput
screen
machin
learn
dock
select
addit
drug
test
propos
herein
repeat
futur
viru
outbreak
sens
vu
probabl
repeat
next
viru
outbreak
develop
broaderspectrum
antivir
time
hope
better
prepar
hope
howev
save
live
effect
antivir
treatment
need
readi
futur
